Condition: Pulmonary Hypertension · Interstitial Lung Disease (ILD) · Sponsor: Tempus AI
MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.
This description comes directly from the study's public registry record.
Momentous Study · (833) 514-4187 · momentous-study@tempus.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Banner University Medical Center | Phoenix, Arizona, United States | Recruiting |
| Dignity Health - St. Joseph's Hospital and Medical Center-Norton Thoracic Institute | Phoenix, Arizona, United States | Recruiting |
| National Jewish Health | Denver, Colorado, United States | Recruiting |
| AdventHealth Orlando | Orlando, Florida, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| University of Illinois Health | Chicago, Illinois, United States | Recruiting |
| Indiana University Health Methodist Hospital | Indianapolis, Indiana, United States | Recruiting |
| Community Health Network | Indianapolis, Indiana, United States | Recruiting |
| University of Kentucky | Lexington, Kentucky, United States | Recruiting |
| Louisiana State University Health Shreveport | Shreveport, Louisiana, United States | Recruiting |
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06911632